PBT2 and zinc work together to fight antibiotic resistance, page-18

This has been a couple of days now with nothing but silence from Prana. Call me a cynic, but this does not pass the smell test. Just saying one possibility and someone had to say it. Continued silence would border on suspect behavior IMO, so I think Prana should make some statement on the publication to provide clarity for current investors now that study result is out there. For instance do Prana have use with antibiotics covered in IP. 
ASX Continuous Disclosure Rules:
This Guide is published to assist listed entities and their officers to understand and comply with their disclosureobligations under Listing Rules 3.1 and 3.1A. These rules provide:
3.1 Once an entity is or becomes aware of any information concerning it that a reasonable person wouldexpect to have a material effect on the price or value of the entity’s securities, the entity must immediatelytell ASX that information.
3.1A Listing rule 3.1 does not apply to particular information while each of the following requirements is satisfiedin relation to the information:3.1A.1 One or more of the following 5 situations applies:
 It would be a breach of a law to disclose the information;
 The information concerns an incomplete proposal or negotiation;
 The information comprises matters of supposition or is insufficiently definite to warrantdisclosure;
 The information is generated for the internal management purposes of the entity; or
 The information is a trade secret; and3.1A.2 The information is confidential and ASX has not formed the view that the information hasceased to be confidential; and
3.1A.3 A reasonable person would not expect the information to be disclosed.